Filters
Dual immunotherapy with checkpoint inhibitors nivolumab and ipilimumab works better to slow disease progression in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) when compared with single-agent nivolumab, as shown in the phase III CheckMate 8HW trial.
The use of gabapentin is effective in reducing neuropathic pain due to paclitaxel chemotherapy, as shown in a study.
A smartphone-based cancer prehabilitation program in Singapore is feasible and safe, with preliminary data showing high acceptability among local users.
In patients with colorectal cancer, a history of allergy, previous oxaliplatin exposure, and chemotherapy regimens appear to increase the risk of having oxaliplatin hypersensitivity reactions, results of a recent study have shown.
A study from Singapore shows that targeted therapies such as bevacizumab, immune checkpoint inhibitors (ICIs), and secondary cytoreductive surgery (SCS) hold promise for the treatment of ovarian clear cell carcinoma (OCCC).
New drug applications approved by US FDA as of 16-31 January 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.
The use of clozapine appears to slightly increase the risk of haematological malignancy (HM) among patients with schizophrenia compared with olanzapine use, suggests a study.
The disease-free survival outcome in patients with low rectal cancer who receive laparoscopic surgery compares favourably with that in those who receive open surgery, according to a study.
The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.
